InvestorsHub Logo
Followers 25
Posts 7029
Boards Moderated 2
Alias Born 06/11/2020

Re: declaes post# 112002

Monday, 12/13/2021 11:00:23 AM

Monday, December 13, 2021 11:00:23 AM

Post# of 112647
The best you can do is go after the outstanding share count which is less than a million shares? Seriously, there is no possible way that you can out do me in bashing this stock this year. I was bashing this stock when it wasn’t cool and traders were making love to it. LOL That being said, the wild card is Jason and his acquisition wish lists that have battered this stock over the past couple of years and two reverse splits. The question right now is if there is a plan that deviates from past practice or if past practice has finally created something that creates shareholder value.

I know the history very well and though it is a despised stock the technicals are quite different now. 743k outstanding shares at the end of Q1 and 945K now so added 202K since. They have a $150K payment for financing that is due each month. It is creating a problem at the moment because of the current liquidity but it is much better than converting that number at twice the face value like notes of the past. The positives are the year over year numbers and $1.3 million in cash on-hand as of Q3, claimed 99.9% customer retention rate for 2021, Nice year over year revenue gains, working on corporate governance issues… The negatives would be Jason's apparent contempt for shareholders, the outstanding Centurion deal since Jason hasn’t explained its value, and the sentiment driven liquidity problem in the face of needed monthly conversions to service the debt. The liabilities at his point are under $4 million.

February 23rd 2021 the reverse split is known and the price drops about 85% from $68 to $10 on the day of the actual split of July 1st. Now the stock is down nearly another 90%. I guess the question at the moment is when do the positives indicate oversold.



Q3 2020 filing
https://sec.report/Document/0001493152-20-021394/
Common Stock

The Company is authorized to issue 1,500,000,000 shares of common stock with a par value of $0.001. All shares have equal voting rights, are non-assessable, and have one vote per share. The total number of shares of Company common stock issued and outstanding as of September 30, 2020 and December 31, 2019, respectively, was 607,077,018 and 9,692,065 shares, respectively.

Total current liabilities $9,656,268
Cash $482,715
Total current assets $568,714
Revenue $700,275
Cost of revenue $108,363
Gross profit $591,912

Share count 607,077,018 / 2000 = 303,539

($9,656,268 - $591,912) / 303,539
$9,064,356 / 303,539 = (29.86) negative value



Q3 2021 filing.
https://sec.report/Document/0001493152-21-026340/

As of September 30, 2021, the Company is authorized to issue 1,000,000,000 shares of common stock with a par value of $0.001. All shares have equal voting rights, are non-assessable, and have one vote per share. The total number of shares of Company common stock issued and outstanding as of September 30, 2021 and December 31, 2020, respectively, was 829,518 and 522,006 shares, respectively.

Total Current Liabilities $3,890,393

Cash $1,377,579
Total current assets $1,489,798

Revenue $1,495,059
Cost of revenue $148,721
Gross profit $1,346,338

Share count 829,518


($3,890,393 - $1,346,338) / 303,539 (same share count as 2020 for comparison sake.)
$2,544,055 / 303,539 = -8.38




https://www.otcmarkets.com/stock/ATDS/security
Outstanding Shares -----945,316------11/30/2021

https://sec.report/Document/0001493152-21-018448/
Common Stock
As of June 30, 2021, the Company is authorized to issue 1,000,000,000 shares of common stock with a par value of $0.001. All shares have equal voting rights, are non-assessable, and have one vote per share. The total number of shares of Company common stock issued and outstanding as of June 30, 2021 and December 31, 2020, respectively, was 743,246 and 522,006 shares, respectively.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATDS News